01:15 PM EDT, 05/01/2025 (MT Newswires) -- 180 Life Sciences ( ATNF ) said Thursday that the US Patent and Trademark Office has issued a notice of allowance for a patent application covering a new method to prevent post-operative cognitive dysfunction, or POCD.

The patent centers on preventing or reducing POCD by using an anti-human tumor necrosis factor alpha monoclonal antibody before and during surgery.

POCD is a complication affecting elderly surgical patients that leads to delirium, memory loss, and other cognitive impairments, the company said.

180 Life Sciences ( ATNF ) said a patent, if issued, would boost its biotechnology portfolio while it shifts focus toward online casino and entertainment ventures through its gaming platform.

Shares of 180 Life Sciences ( ATNF ) were up 11% in recent Thursday trading.

Price: 0.99, Change: +0.10, Percent Change: +11.01